Katharine Cioe1, Breanne E Biondi2, Rebecca Easly1, Amanda Simard1, Xiao Zheng3, Sandra A Springer4. 1. Frank H. Netter MD School of Medicine, 370 Bassett Road, North Haven, CT 06473, United States of America. 2. Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, United States of America. 3. Yale University, New Haven, CT 06520, United States of America. 4. Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, United States of America; Center for Interdisciplinary Research on AIDS, Yale University School of Public Health, New Haven, CT, United States of America. Electronic address: Sandra.springer@yale.edu.
Abstract
BACKGROUND: The opioid epidemic is a public health crisis. Medications for opioid use disorder (MOUD) include: 1) buprenorphine, 2) methadone, and 3) extended-release naltrexone (XR-NTX). Research should investigate patients' and providers' perspectives of MOUD since they can influence prescription, retention, and recovery. METHODS: This systematic review focused on patients' and providers' perceptions of MOUD. The review eligibility criteria included inclusion of the outcome of interest, in English, and involving persons ≥18 years. A PubMed database search yielded 1692 results; we included 152 articles in the final review. RESULTS: There were 63 articles about buprenorphine, 115 articles about methadone, and 16 about naltrexone. Misinformation and stigma associated with MOUD were common patient themes. Providers reported lack of training and resources as barriers to MOUD. CONCLUSION: This review suggests that patients have significant misinformation regarding MOUD. Due to the severity of the opioid epidemic, research must consider the effects of patients' and providers' perspectives on treatment for OUD, including the effects on the type of MOUD prescribed, patient retention and adherence, and ultimately the number of patients treated for OUD, which will aid in curbing the opioid epidemic. Published by Elsevier Inc.
BACKGROUND: The opioid epidemic is a public health crisis. Medications for opioid use disorder (MOUD) include: 1) buprenorphine, 2) methadone, and 3) extended-release naltrexone (XR-NTX). Research should investigate patients' and providers' perspectives of MOUD since they can influence prescription, retention, and recovery. METHODS: This systematic review focused on patients' and providers' perceptions of MOUD. The review eligibility criteria included inclusion of the outcome of interest, in English, and involving persons ≥18 years. A PubMed database search yielded 1692 results; we included 152 articles in the final review. RESULTS: There were 63 articles about buprenorphine, 115 articles about methadone, and 16 about naltrexone. Misinformation and stigma associated with MOUD were common patient themes. Providers reported lack of training and resources as barriers to MOUD. CONCLUSION: This review suggests that patients have significant misinformation regarding MOUD. Due to the severity of the opioid epidemic, research must consider the effects of patients' and providers' perspectives on treatment for OUD, including the effects on the type of MOUD prescribed, patient retention and adherence, and ultimately the number of patients treated for OUD, which will aid in curbing the opioid epidemic. Published by Elsevier Inc.
Entities:
Keywords:
Buprenorphine/naloxone; MOUD, buprenorphine; Methadone; Opioid use disorder; XR-naltrexone
Authors: Kelly Alanis-Hirsch; Raina Croff; James H Ford; Kim Johnson; Mady Chalk; Laura Schmidt; Dennis McCarty Journal: J Subst Abuse Treat Date: 2015-11-06
Authors: Valerie S Harder; Andrea C Villanti; Sarah H Heil; M Lindsey Smith; Diann E Gaalema; Marjorie C Meyer; Nathaniel H Schafrick; Stacey C Sigmon Journal: Prev Med Date: 2021-08-16 Impact factor: 4.018
Authors: Derjung M Tarn; Kevin J Shih; Allison J Ober; Sarah B Hunter; Katherine E Watkins; Jeremy Martinez; Alanna Montero; Michael McCreary; Isabel Leamon; John Sheehe; Elizabeth Bromley Journal: Community Ment Health J Date: 2022-07-29
Authors: Julia Dickson-Gomez; Antoinette Spector; Margaret Weeks; Carol Galletly; Madelyn McDonald; Helena Danielle Green Montaque Journal: Subst Abuse Date: 2022-06-27
Authors: Jessica Heil; Valerie S Ganetsky; Matthew S Salzman; Krystal Hunter; Kaitlan E Baston; Gerard Carroll; Eric Ketcham; Rachel Haroz Journal: West J Emerg Med Date: 2022-04-04
Authors: Natalie M Brousseau; Heather Farmer; Allison Karpyn; Jean-Philippe Laurenceau; John F Kelly; Elizabeth C Hill; Valerie A Earnshaw Journal: J Subst Abuse Treat Date: 2021-08-09
Authors: Amanda R Liberman; Daniel J Bromberg; Lyuba Azbel; Julia Rozanova; Lynn Madden; Jaimie P Meyer; Frederick L Altice Journal: Int J Drug Policy Date: 2021-04-07
Authors: Holly J Lanham; Jennifer Papac; Daniela I Olmos; Emily L Heydemann; Nathalia Simonetti; Susanne Schmidt; Jennifer S Potter Journal: JAMA Netw Open Date: 2022-05-02
Authors: Tara Gomes; Daniel McCormack; Nikki Bozinoff; Mina Tadrous; Tony Antoniou; Charlotte Munro; Tonya Campbell; J Michael Paterson; Muhammad Mamdani; Beth Sproule Journal: Addiction Date: 2022-03-21 Impact factor: 7.256